Exploring user preferences for PrEP service delivery models in Japan: a discrete choice experiment among men who have sex with men
Chunyan Li






A
B
C
D
E
F
G
H
I
J
# These authors contributed equally to this paper
Handling Editor: Adam Hill
Abstract
High cost and limited PrEP providers impede PrEP uptake for Japanese users. Our study aims to investigate PrEP use behaviors and preferences for PrEP among men who have sex with men (MSM) in Japan.
PrEP APPEAL was an online cross-sectional survey conducted in Japan to assess PrEP preferences among adult MSM using a discrete choice experiment design. Data were collected between May 2022 and November 2022. Participants were primarily recruited through gay dating apps and community-based referral. Mixed logit modeling with effects coding was applied to estimate preference weightings and individual segments with heterogeneous preferences.
A total of 1358 participants were included (mean age 39.3 years, s.d. 11.2 years); 98.5% were assigned male at birth, and 78.4% identified as gay men. Only 13.5% were current PrEP users. Participants ranked monthly service cost (46.2%) as the most important PrEP attribute, followed by side effects (21.7%), PrEP type (14.5%), access locations (6.3%), visit frequency (5.8%) and additional services (5.6%). They were highly sensitive to cost increases (β = −0.33, P < 0.001), preferred options with no side effects (β = 0.63, P < 0.001) and comprehensive STI testing (β = 0.19, P < 0.001). On-demand (β = 0.32, P < 0.001) and monthly oral dosing (β = 0.34, P < 0.001) were preferred, whereas slow-release implants were less preferred (β = −0.49, P < 0.001). Care through MSM-operated clinics (β = 0.21, P < 0.001) or pharmacies (β = 0.12, P = 0.047) was preferred over hospitals (β = −0.15, P = 0.031). Longer visit intervals of 6 months (β = 0.11, P = 0.015) or annually (β = 0.11, P = 0.006) were preferred over shorter intervals.
Affordable PrEP options with minimal side effects and care provision through community-led clinics are generally preferred by Japanese MSM. Developing a decentralized PrEP delivery model that aligns with user preferences is essential to help Japan accelerate its goals to end the HIV epidemic by 2030.
Keywords: community health, discrete choice experiment, healthcare delivery model, HIV, Japan, men who have sex with men, pre-exposure prophylaxis, prevention, stated preference research.
References
1 Iwata K, Miyakoshi C. Can Japan achieve zero transmission of HIV? Time series analysis using bayesian local linear trend model. Kobe J Med Sci 2021; 66(5): E175-E179.
| Google Scholar | PubMed |
2 AIDS Surveillance Committee, Ministry of Health, Labour and Welfare, Japan (厚生労働省エイズ動向委員会). Overview of HIV/AIDS incidence trends in 2023 (Reiwa 5); 2024. Available at https://api-net.jfap.or.jp/status/japan/data/2023/nenpo/r05gaiyo.pdf [in Japanese] [accessed 22 December 2024]
3 Iwamoto A, Taira R, Yokomaku Y, et al. The HIV care cascade: Japanese perspectives. PLoS ONE 2017; 12(3): e0174360.
| Crossref | Google Scholar | PubMed |
4 Jimba M, Suzuki M, Kitamura T, Carandang RR, Sieber NL. Risk of increasing the sudden diagnosis of AIDS in Japan during and after the COVID-19 Outbreak. JMA J 2021; 5(1): 104-106.
| Crossref | Google Scholar | PubMed |
5 Usami C. HIV treatment drug truvada approved for pre-exposure prophylaxis: Nikkei Medical (HIV治療薬ツルバダ、曝露前予防の承認取得:日経メディカル). Nikkei Medical. 2024. Available at https://medical.nikkeibp.co.jp/leaf/mem/pub/hotnews/int/202408/585551.html [in Japanese] [accessed 22 December 2024]
6 Terada-Hirashima J, Mizushima D, Takano M, Tokita D, Oka S. Efficacy and safety of pre-exposure prophylaxis to control HIV and sexually transmitted infection among men who have sex with men: protocol for a single-arm interventional study. JMIR Res Protoc 2023; 12: e50919.
| Crossref | Google Scholar |
7 Mizushima D, Gatanaga H, Oka S. Advances in HIV management and challenges in Japan: current situation of pre-exposure prophylaxis in Tokyo. Glob Health Med 2024; 6(5): 304-309.
| Crossref | Google Scholar | PubMed |
8 Pharmaceuticals and Medical Devices Bureau, Ministry of Health, Labour and Welfare (厚生労働省医薬局). Q&A on procedures for importing pharmaceuticals and related products (as of March 26, 2024 [Reiwa 6]) 医薬品等輸入手続質疑応答集(Q&A)(令和6年3月26日版). 2024. Available at https://www.mhlw.go.jp/content/001070072.pdf [in Japanese] [accessed 22 December 2024]
9 HIVmap. In-depth explanation about PrEP: what exactly changes now that Truvada has been approved? (ツルバダが薬事承認されて、何がどう変わるのか?). hiv-map.net. 2024. Available at https://hiv-map.net/post/truvada-prep-approved/ [in Japanese] [accessed 22 December 2024]
10 Ikishima T, Yamaguchi M, Miwa T, Otsuki T. Survey report on sexual life and PrEP (「セックスライフとPrEPについてのアンケート調査」報告書). 2022. Available at https://prep.ptokyo.org/wp/wp-content/uploads/2022/04/prepinjapan_report_R3.pdf [in Japanese] [accessed 22 December 2024]
11 Oxford Analytica. Low savings limit Japanese spending and GDP growth. 2024. Available at https://www.emerald.com/insight/content/doi/10.1108/oxan-db285796/full/html
12 Chan C, Fraser D, Schmidt HM, et al. PrEP product awareness, preferences, and past experiences among transgender women and men who have sex with men in Asia and Australia: the PrEP APPEAL study report. UNSW Sydney; 2023. Available at http://doi.org/10.26190/9bd4-w424
13 Tieosapjaroen W, Bavinton BR, Schmidt H-MA, et al. Preferences for HIV pre-exposure prophylaxis among men who have sex with men and trans women in 15 countries and territories in Asia and Australia: a discrete choice experiment. J Int AIDS Soc 2025; 28(8): e70025.
| Crossref | Google Scholar | PubMed |
14 Howell M, Howard K. Eliciting preferences from Choices: discrete choice experiments. In: P Liamputtong. Handbook of Research Methods in Health Social Sciences. Singapore: Springer; 2019, pp. 623–644. doi:10.1007/978-981-10-5251-4_93
15 Wulandari LPL, He SY, Fairley CK, et al. Preferences for pre-exposure prophylaxis for HIV: a systematic review of discrete choice experiments. eClinicalMedicine 2022; 51: 101507.
| Crossref | Google Scholar | PubMed |
16 Lancsar E, Louviere J. Conducting discrete choice experiments to inform healthcare decision making: a user’s guide. PharmacoEconomics 2008; 26(8): 661-677.
| Crossref | Google Scholar | PubMed |
17 Kleinman L, McIntosh E, Ryan M, et al. Willingness to pay for complete symptom relief of gastroesophageal reflux disease. Arch Intern Med 2002; 162(12): 1361-1366.
| Crossref | Google Scholar | PubMed |
18 Mayer KH, Agwu A, Malebranche D. Barriers to the wider use of pre-exposure prophylaxis in the United States: a narrative review. Adv Ther 2020; 37(5): 1778-1811.
| Crossref | Google Scholar | PubMed |
19 Espera JR, Reyes CA, Sarmiento EG, Sitchon CM, Zantua R, Carandang RR. Acceptability and feasibility of HIV pre-exposure prophylaxis (PrEP) in Southeast Asia: a scoping review. Int J STD AIDS 2025; 36(4): 260-274.
| Crossref | Google Scholar | PubMed |
20 Patel RR, Mena L, Nunn A, et al. Impact of insurance coverage on utilization of pre-exposure prophylaxis for HIV prevention. PLoS ONE 2017; 12(5): e0178737.
| Crossref | Google Scholar |
21 Doblecki-Lewis S, Liu A, Feaster D, et al. Healthcare access and PrEP continuation in San Francisco and Miami after the US PrEP Demo Project. J Acquir Immune Defic Syndr 2017; 74(5): 531-538.
| Crossref | Google Scholar | PubMed |
22 Tan DHS, Dashwood TM, Wilton J, Kroch A, Gomes T, Martins D. Trends in HIV pre-exposure prophylaxis uptake in Ontario, Canada, and impact of policy changes: a population-based analysis of projected pharmacy data (2015–2018). Can J Public Health 2021; 112(1): 89-96.
| Crossref | Google Scholar |
23 de Aguiar Pereira CC, Torres TS, Luz PM, et al. Preferences for pre-exposure prophylaxis (PrEP) among sexual and gender minorities: a discrete choice experiment in Brazil. Lancet Reg Health Am 2023; 19: 100432.
| Crossref | Google Scholar | PubMed |
24 Cole SW, Glick JL, Campoamor NB, et al. Willingness and preferences for long-acting injectable PrEP among US men who have sex with men: a discrete choice experiment. BMJ Open 2024; 14(4): e083837.
| Crossref | Google Scholar | PubMed |
25 O Murchu E, Marshall L, Teljeur C, et al. Oral pre-exposure prophylaxis (PrEP) to prevent HIV: a systematic review and meta-analysis of clinical effectiveness, safety, adherence and risk compensation in all populations. BMJ Open 2022; 12(5): e048478.
| Crossref | Google Scholar |
26 Japan Registry of Clinical Trials #jRCTs031180134. Clinical trial for pre-exposure prophylaxis for HIV infection toward Tokyo Olympic. 2022. Available at https://jrct.niph.go.jp/en-latest-detail/jRCTs031180134 [accessed 5 January 2025]
27 Takahashi T, Baba T, Ogawa T, et al. Age-specific distribution of estimated glomerular filtration rate using Japanese health checkup data. HEP 2016; 43(4): 518-524.
| Crossref | Google Scholar |
28 Takamatsu N, Abe H, Tominaga T, et al. Risk factors for chronic kidney disease in Japan: a community-based study. BMC Nephrol 2009; 10: 34.
| Crossref | Google Scholar | PubMed |
29 Tagliaferri Rael C, Giguere R, Sutton S, et al. Preferences among physicians and men who have sex with men (MSM) for a long-acting, removable implant for HIV prevention: a discrete choice study. AIDS Research and Human Retroviruses 2022; 38(12): 898-908.
| Crossref | Google Scholar | PubMed |
30 Sun J, Ong JJ, Schmidt HM, et al. Preferences and willingness to use pre-exposure prophylaxis for HIV among men who have sex with men in mainland China and Hong Kong. Sex Health 2025; 22: SH24247.
| Crossref | Google Scholar |
31 Greene GJ, Swann G, Fought AJ, et al. Preferences for long-acting pre-exposure prophylaxis (PrEP), daily oral PrEP, or condoms for HIV prevention among US men who have sex with men. AIDS Behav 2017; 21(5): 1336-1349.
| Crossref | Google Scholar | PubMed |
32 Minnis AM, Atujuna M, Browne EN, et al. Preferences for long-acting Pre-Exposure Prophylaxis (PrEP) for HIV prevention among South African youth: results of a discrete choice experiment. J Int AIDS Soc 2020; 23(6): e25528.
| Crossref | Google Scholar | PubMed |
33 Arnold B. Micro-apartments: a movement to smaller living spaces in Japan. MSJ 2024; 1(2): 152-170.
| Crossref | Google Scholar |
34 Ronald R, Hirayama Y. Home alone: the individualization of young, urban Japanese singles. Environ Plan A 2009; 41(12): 2836-2854.
| Crossref | Google Scholar |
35 DiStefano AS. HIV in Japan: epidemiologic puzzles and ethnographic explanations. SSM Popul Health 2016; 2: 436-450.
| Crossref | Google Scholar | PubMed |
36 Li C, Xiong Y, Liu H, et al. Multifaceted barriers to rapid roll-out of HIV pre-exposure prophylaxis in China: a qualitative study among men who have sex with men. Int J Behav Med 2024; 31(2): 252-262.
| Crossref | Google Scholar |
37 Brisson J, Ravitsky V, Williams-Jones B. Informal PrEP: an emerging need for nomenclature. Lancet Public Health 2019; 4(2): e83.
| Crossref | Google Scholar | PubMed |
38 Rivierez I, Quatremere G, Spire B, Ghosn J, Rojas Castro D. Lessons learned from the experiences of informal PrEP users in France: results from the ANRS-PrEPage study. AIDS Care 2018; 30(sup2): 48-53.
| Crossref | Google Scholar | PubMed |
39 Kamakura M, Fukuda D, Kuroishi N, Ainiwaer D, Hattori J. Exploring current practice, knowledge, and challenges of sexually transmitted infection/HIV Management and pre-exposure prophylaxis among Japanese health care professionals: a cross-sectional web survey. AIDS Patient Care STDS 2023; 37(5): 253-267.
| Crossref | Google Scholar | PubMed |
40 Phanuphak N, Sungsing T, Jantarapakde J, et al. Princess PrEP program: the first key population-led model to deliver pre-exposure prophylaxis to key populations by key populations in Thailand. Sex Health 2018; 15(6): 542-555.
| Crossref | Google Scholar | PubMed |
41 Reza-Paul S, Lazarus L, Maiya R, et al. The Ashodaya PrEP project: lessons and implications for scaling up PrEP from a community-led demonstration project among female sex workers in Mysore, India. Glob Public Health 2020; 15(6): 889-904.
| Crossref | Google Scholar | PubMed |
42 Doan AH, Vu CMH, Nguyen TT, et al. Caring for the whole person: transgender-competent HIV pre-exposure prophylaxis as part of integrated primary healthcare services in Vietnam. J Int AIDS Soc 2022; 25(Suppl 5): e25996.
| Crossref | Google Scholar |
43 Lau JY, Hung C-T, Lee S-S. A review of HIV pre-exposure prophylaxis (PrEP) programmes by delivery models in the Asia-Pacific through the healthcare accessibility framework. J Intern AIDS Soc 2020; 23(7): e25531.
| Crossref | Google Scholar |
44 Tapa J, Kusen M, Young F, Merrigan M, Ong JJ. Financial sustainability of HIV services for key populations in four countries in Asia: a mixed-methods study. Sex Health 2025; 22(3): SH24210.
| Crossref | Google Scholar |
45 Brink DT, Martin-Hughes R, Bowring AL, et al. Impact of an international HIV funding crisis on HIV infections and mortality in low-income and middle-income countries: a modelling study. Lancet HIV 2025; 12(5): e346-e354.
| Crossref | Google Scholar | PubMed |
46 World Health Organization. Differentiated and simplified pre-exposure prophylaxis for HIV prevention: update to WHO implementation guidance. Technical Brief. World Health Organization; 2022. Available at https://www.who.int/publications/i/item/9789240053694
47 Veldwijk J, Marceta SM, Swait JD, Lipman SA, De Bekker-Grob EW. Taking the shortcut: simplifying heuristics in discrete choice experiments. Patient 2023; 16(4): 301-315.
| Crossref | Google Scholar | PubMed |
48 Salkeld G, Ryan M, Short L. The veil of experience: do consumers prefer what they know best? Health Econ 2000; 9(3): 267-270.
| Crossref | Google Scholar | PubMed |